Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

References

• TaylorDDuncan-McConnellDRefractory schizophrenia and atypical antipsychoticsJ Psychopharmacol20001440941811198061
   PubMed Web of Science ®Google Scholar
• MeltzerHYTreatment-resistant schizophrenia – the role of clozapineCurr Med Res Opin1997141209524789
   PubMed Web of Science ®Google Scholar
• SwartzMStroupTMcEvoyJWhat CATIE found: Results from the schizophrenia trialPsychiatr Serv20085950050618451005
   PubMed Web of Science ®Google Scholar
• MeltzerHAlphsLGreenAInternational Suicide Prevention Trial Study GroupClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Arch Gen Psychiatry200360829112511175
   PubMed Web of Science ®Google Scholar
• TiihonenJLönnqvistJWahlbeckK11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11study)Lancet20092262062719595447
   PubMed Web of Science ®Google Scholar
• SernyakMJDesaiRStolarMRosenheckRImpact of clozapine on completed suicideAm J Psychiatry200115893193711384902
   PubMed Web of Science ®Google Scholar
• de HertMCorrellCCohenDDo antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN- 11studySchizophr Res2010117687420060684
   PubMed Web of Science ®Google Scholar
• AtkinsonJMDouglas-HallPFischettiCSparshattATaylorDMOutcome following clozapine discontinuation: A retrospective analysisJ Clin Psychiatry2007681027103017685738
   PubMed Web of Science ®Google Scholar
• DratcuLGrandisonAMcKayGBamideleAVasudevanVClozapine-resistant psychosis, smoking, and caffeine: Managing the neglected effects of substances that our patients consume every dayAm J Ther20071431431817515710
   PubMedGoogle Scholar
• AlvirJLiebermanJSaffermanASchwimmerJSchaafJClozapine-induced agranulocytosis. Incidence and risk factors in the United StatesN Engl J Med19933291621678515788
   PubMed Web of Science ®Google Scholar
• StahlSGradyMA critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentationCurr Med Chem20041131332714965234
   PubMed Web of Science ®Google Scholar
• WassefADottSHarrisACritical review of GABA-ergic drugs in the treatment of schizophreniaJ Clin Psychopharmacol19991922223210350028
   PubMed Web of Science ®Google Scholar
• TuominenHJTiihonenJWahlbeckKGlutamatergic drugs for schizophreniaCochrane Database Syst Rev200619CD00373016625590
   PubMedGoogle Scholar
• TributOBentué-FerrerDVerdierMCTherapeutic drug monitoring of gabapentinTherapie2010655760 French20205997
   PubMed Web of Science ®Google Scholar
• LandmarkCJTargets for antiepileptic drugs in the synapseMed Sci Monit200713RA1717179916
   PubMed Web of Science ®Google Scholar
• NgGBernardSSullivanRGamma-aminobutyric acid Type B receptors with specific heterodimer composition and post synaptic action in the hippocampal neurons are targets of anticonvulsant gabapentin actionMol Pharmacol20015914415211125035
   PubMed Web of Science ®Google Scholar
• SillsGThe mechanism of action of gabapentin and pregabalinCurr Opin Phamacol20066108113
   PubMed Web of Science ®Google Scholar
• MaraisEKlughauerNHofmanFCalcium channel alpha (2) delta subunit structure and gabapentin bindingMol Pharmacol2001591243124811306709
   PubMed Web of Science ®Google Scholar
• HandforthATreimanMEfficacy and tolerance of long term, high dose gabapentin: Additional observationsEpilepsia199435103210377925148
   PubMed Web of Science ®Google Scholar
• GoaKSorkinEGabapentin: A review of its pharmacological properties and clinical potential in epilepsyDrugs1993464094277693432
   PubMed Web of Science ®Google Scholar
• DemilyCFranckNGabapentin for ultra resistant schizophrenia with aggressive behaviorSchizophr Res200810034935018255272
   PubMed Web of Science ®Google Scholar
• MegnaJLDevittPJSauroMDDewanMJGabapentin’s effect on agitation in severely and persistently mentally ill patientsAnn Pharmacother200236121611816241
   PubMed Web of Science ®Google Scholar
• CabrasPLHardoyMJHardoyMCCartaMGClinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label studyJ Clin Psychiatry19996024524810221286
   PubMed Web of Science ®Google Scholar
• BennettJGoldmanWTSuppesTGabapentin for treatment of bipolar and schizoaffective disordersJ Clin Psychopharmacol19971714114210950494
   PubMed Web of Science ®Google Scholar
• PfefferGChouinardGMargoleseHCGabapentin in the treatment of antipsychotic-induced akathisia in schizophreniaInt Clin Psychopharmacol20052017918115812271
   PubMed Web of Science ®Google Scholar
• HardoyMCartaMCarpinielloBGabapentin in antipsychotic-induced tardive dyskinesia: Results of 1-year follow-upJ Affect Disord20037512513012798252
   PubMed Web of Science ®Google Scholar
• UsiskinSNicolosonRLenaneMRapoportJGabapentin prophylaxis of clozapine induced seizuresAm J Psychiatry200015748248310698845
   PubMed Web of Science ®Google Scholar
• SheehanDVLecrubierYSheehanKHThe Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10J Clin Psychiatry199859Suppl 2022339881538
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and the negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871379103
   Web of Science ®Google Scholar
• AddingtonDAddingtonJMaticka-TyndaleESpecificity of the Calgary Depression Scale for SchizophreniaSchizophr Res1994112392448193062
   PubMed Web of Science ®Google Scholar
• ChouinardGChouinard-RossAAnnableLJonesBExtrapyramidal rating scaleCan J Neurol Sci19807233
   Web of Science ®Google Scholar
• LeuchtSDavidJEngelRKisslingWKaneJDefinition of response and remission in schizophrenia: Recommendation for their use and their presentationActa Psychiatr Scand2009119714
   Web of Science ®Google Scholar
• RogawskiMAstrocytes get in the act in epilepsyNat Med20051191992016145568
   PubMed Web of Science ®Google Scholar
• BenesFMThe role of stress and dopamine-GABA interactions in the vulnerability for schizophreniaJ Psychiatr Res1997312572759278189
   PubMed Web of Science ®Google Scholar
• TammingaCACraytonJCChaseTNMuscimol: GABA agonist therapy in schizophreniaAm J Psychiatry1978135746748350058
   PubMed Web of Science ®Google Scholar
• KoranLGamma aminobutyric acid deficiency in schizophreniaLancet19762102562243
   PubMed Web of Science ®Google Scholar
• BowdenCLNew concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigineNeuropsychopharmacology1998191941999653707
   PubMed Web of Science ®Google Scholar
• JohannessenCAntiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacyCNS Drugs200822274718072813
   PubMed Web of Science ®Google Scholar
• RogawskiMALöscherWThe neurobiology of antiepileptic drugs for the treatment of nonepileptic conditionsNat Med20041068569215229516
   PubMed Web of Science ®Google Scholar
• YathamLNKennedySHO’DonovanCGuidelines Group, CANMATCanadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorderBipolar Disord2006872173917156158
   PubMed Web of Science ®Google Scholar
• HosákLLibigerJAntiepileptic drugs in schizophrenia: A reviewEur Psychiatry20021737137812547302
   PubMed Web of Science ®Google Scholar
• BarnesTREMcEvedyCJBNelsonHEManagement of treatment-resistant schizophrenia unresponsive to clozapineBr J Psychiatry1996169Suppl 313140
   Web of Science ®Google Scholar
• TiihonenJWahlbeckKKiviniemiVThe efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta- analysisSchizophr Res2009109101419186030
   PubMed Web of Science ®Google Scholar
• LargeCHWebsterELGoffDCThe potential role of lamotrigine in schizophreniaPsychopharmacology200518141543616001126
   PubMed Web of Science ®Google Scholar
• GoffDCKeefeRCitromeLLamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trialsJ Clin Psychopharmacol20072758258918004124
   PubMed Web of Science ®Google Scholar
• BenesFBerrettaSGABAergic interneurons: Implications for understanding schizophrenia and bipolar disorderNeuropsychopharmacology20012512711377916
   PubMed Web of Science ®Google Scholar